138 related articles for article (PubMed ID: 4551793)
1. Studies of endogenous catecholamines in patients with Raynaud's phenomenon secondary to progressive systemic sclerosis (scleroderma).
Sapira JD; Rodnan GP; Scheib ET; Klaniecki T; Rizk M
Am J Med; 1972 Mar; 52(3):330-7. PubMed ID: 4551793
[No Abstract] [Full Text] [Related]
2. Progressive systemic sclerosis sine scleroderma in a child presenting as nocturnal seizures and Raynaud's phenomenon.
Navon P; Halevi A; Brand A; Branski D; Rubinow A
Acta Paediatr; 1993 Jan; 82(1):122-3. PubMed ID: 8453211
[TBL] [Abstract][Full Text] [Related]
3. Prazosin for Raynaud's phenomenon in progressive systemic sclerosis.
Pope J; Fenlon D; Thompson A; Shea B; Furst D; Wells G; Silman A
Cochrane Database Syst Rev; 2000; 1998(2):CD000956. PubMed ID: 10796398
[TBL] [Abstract][Full Text] [Related]
4. [Botulinum toxin type A contribution in the treatment of Raynaud's phenomenon due to systemic sclerosis].
Serri J; Legré R; Veit V; Guardia C; Gay AM
Ann Chir Plast Esthet; 2013 Dec; 58(6):658-62. PubMed ID: 22204894
[TBL] [Abstract][Full Text] [Related]
5. [Esophageal motility in Raynaud's disease, systemic scleroderma and presclerodermal Raynaud's syndrome].
Hostein J; Bost R; Carpentier P; Franco A; Fournet J
Gastroenterol Clin Biol; 1985 Feb; 9(2):130-5. PubMed ID: 3979734
[TBL] [Abstract][Full Text] [Related]
6. Effect of prostaglandins I2 and E1 on red cell deformability in patients with Raynaud's phenomenon and systemic sclerosis.
Dowd PM; Kovacs IB; Bland CJ; Kirby JD
Br Med J (Clin Res Ed); 1981 Aug; 283(6287):350. PubMed ID: 6788326
[No Abstract] [Full Text] [Related]
7. [Raynaud's phenomena: diagnostic and treatment study].
Priollet P
Rev Prat; 1998 Oct; 48(15):1659-64. PubMed ID: 9814067
[TBL] [Abstract][Full Text] [Related]
8. Cold-induced changes in plasma norepinephrine, epinephrine and dopamine concentrations in patients with Raynaud's phenomenon.
Marasini B; Biondi ML; Mollica R; Del Santo A; Agostoni A
Eur J Clin Chem Clin Biochem; 1991 Feb; 29(2):111-4. PubMed ID: 2049479
[TBL] [Abstract][Full Text] [Related]
9. Current drug therapy for scleroderma and secondary Raynaud's phenomenon: evidence-based review.
Henness S; Wigley FM
Curr Opin Rheumatol; 2007 Nov; 19(6):611-8. PubMed ID: 17917543
[TBL] [Abstract][Full Text] [Related]
10. Role of cold and emotional stress in Raynaud's disease and scleroderma.
Freedman RR; Ianni P
Br Med J (Clin Res Ed); 1983 Nov; 287(6404):1499-502. PubMed ID: 6416474
[TBL] [Abstract][Full Text] [Related]
11. Increased urinary pyridinoline cross-link compounds of collagen in patients with systemic sclerosis and Raynaud's phenomenon.
Istok R; Czirják L; Lukác J; Stancíková M; Rovenský J
Rheumatology (Oxford); 2001 Feb; 40(2):140-6. PubMed ID: 11257149
[TBL] [Abstract][Full Text] [Related]
12. Responses to nifedipine by patients with Raynaud's disease and Raynaud's phenomenon secondary to another disease.
Riccio A; Del Puente A; Farinaro C; Scarpa R; Oriente P; Rocco P; Gioia M
Clin Ther; 1987; 9(2):232-7. PubMed ID: 3568066
[TBL] [Abstract][Full Text] [Related]
13. Raynaud's phenomenon and systemic sclerosis.
Generini S; Kahaleh B; Matucci-Cerinic M; Pignone A; Lombardi A; Ohtsuka T
Ann Ital Med Int; 1996; 11(2):125-31. PubMed ID: 8974438
[TBL] [Abstract][Full Text] [Related]
14. Effect of ketanserin on Raynaud's phenomenon in progressive systemic sclerosis: a double-blind trial.
Lukác J; Rovenský J; Tauchmannová H; Zitnan D
Drugs Exp Clin Res; 1985; 11(9):659-63. PubMed ID: 3916837
[TBL] [Abstract][Full Text] [Related]
15. Deficiency of calcitonin gene-related peptide in Raynaud's phenomenon.
Bunker CB; Terenghi G; Springall DR; Polak JM; Dowd PM
Lancet; 1990 Dec 22-29; 336(8730):1530-3. PubMed ID: 1979366
[TBL] [Abstract][Full Text] [Related]
16. Effect of clonazepam on Raynaud's phenomenon and fingertip ulcers in scleroderma.
Colakoğlu M; Cobankara V; Akpolat T
Ann Pharmacother; 2007 Sep; 41(9):1544-7. PubMed ID: 17666574
[TBL] [Abstract][Full Text] [Related]
17. [Serial computed thermography for Raynaud's phenomenon of patient with progressive systemic sclerosis (PSS)].
Tomono N; Kuriyama T; Mori M; Takahashi Y; Mitsuda T; Aihara Y; Yokota S
Ryumachi; 1996 Jun; 36(3):522-7. PubMed ID: 8779789
[TBL] [Abstract][Full Text] [Related]
18. Peripheral venous blood concentrations of epinephrine and norepinephrine in primary Raynaud's disease.
PEACOCK JH
Circ Res; 1959 Nov; 7():821-7. PubMed ID: 14431207
[No Abstract] [Full Text] [Related]
19. Effect of topical rosemary essential oil on Raynaud phenomenon in systemic sclerosis.
von Schoen-Angerer T; Deckers B; Henes J; Helmert E; Vagedes J
Complement Ther Med; 2018 Oct; 40():191-194. PubMed ID: 30219447
[TBL] [Abstract][Full Text] [Related]
20. Plasma adrenomedullin and endothelin-1 levels are reduced and Raynaud's phenomenon improved by daily tadalafil administration in male patients with systemic sclerosis.
Rosato E; Letizia C; Proietti M; Aversa A; Menghi G; Rossi C; Torella E; Cotesta D; Petramala L; Bruzziches R; Spera G; Pisarri S; Salsano F
J Biol Regul Homeost Agents; 2009; 23(1):23-9. PubMed ID: 19321043
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
